| Bioactivity | LXQ46 is an orally active inhibitor for protein tyrosine phosphatase 1B (PTP1B), with an IC50 of 0.190 μM. LXQ46 enhances insulin and leptin signaling pathways in insulin-resistant C2C12. LXQ46 ameliorates type 2 diabetes and increases insulin tolerance in mouse models[1]. |
| Target | IC50: 0.190 μM (PTP1B) |
| CAS | 2097148-94-0 |
| Formula | C23H17Br2NO5 |
| Molar Mass | 547.19 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li X, et al., Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors. Eur J Med Chem. 2019 Mar 15;166:178-185. |